Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation

BACKGROUND: Osimertinib (AZD9291) is a third‐generation EGFR‐tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR‐mutant non‐small cell lung cancer (NSCLC). However, acquired resistance to osimertinib...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thorac Cancer
Hauptverfasser: Hayakawa, Daisuke, Takahashi, Fumiyuki, Mitsuishi, Yoichiro, Tajima, Ken, Hidayat, Moulid, Winardi, Wira, Ihara, Hiroaki, Kanamori, Koichiro, Matsumoto, Naohisa, Asao, Tetsuhiko, Ko, Ryo, Shukuya, Takehito, Takamochi, Kazuya, Hayashi, Takuo, Suehara, Yoshiyuki, Takeda Nakamura, Ikuko, Ueno, Toshihide, Kohsaka, Shinji, Mano, Hiroyuki, Takahashi, Kazuhisa
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons Australia, Ltd 2019
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6938756/
https://ncbi.nlm.nih.gov/pubmed/31758670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13255
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge